MARKET

IMCR

IMCR

Immunocore Holdings Plc
NASDAQ
31.65
-0.10
-0.32%
After Hours: 31.65 0 0.00% 17:17 07/01 EDT
OPEN
31.79
PREV CLOSE
31.75
HIGH
32.35
LOW
31.00
VOLUME
828.84K
TURNOVER
--
52 WEEK HIGH
40.71
52 WEEK LOW
27.56
MARKET CAP
1.61B
P/E (TTM)
-56.7815
1D
5D
1M
3M
1Y
5Y
1D
AstraZeneca's Enhertu Wins EU Nod for HER2-Positive Solid Tumors (Revised)
NASDAQ · 18h ago
Immunocore Holdings (IMCR) In Focus As Its Cash Backed Growth Narrative Shapes Valuation
Simply Wall St · 2d ago
Weekly Report: what happened at IMCR last week (0622-0626)?
Weekly Report · 2d ago
IONS Out-Licenses ex-U.S. Rights for Rare Neurology Drug to Recordati
NASDAQ · 5d ago
Here's Why You Should Add Kiniksa Stock to Your Portfolio Now
NASDAQ · 5d ago
Immunocore: KIMMTRAK Is Becoming A Cash Engine For A Much Larger TCR Platform
Seeking Alpha · 06/24 12:34
NVO Gains as Foundation Unveils EUR 60M Cardiometabolic Research Push
NASDAQ · 06/23 15:07
How Investors May Respond To Immunocore (IMCR) Melanoma Data Highlighting Brenetafusp’s Potential In PD‑1‑Resistant Disease
Simply Wall St · 06/22 23:29
More
About IMCR
Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a pipeline of clinical-stage programs in oncology and infectious diseases, as well as numerous pre-clinical projects. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, IMC-I109V, IMC-S118AI, and IMC-U120AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, ovarian, lung, colorectal and others.

Webull offers Immunocore Holdings PLC - ADR stock information, including NASDAQ: IMCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMCR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading IMCR stock methods without spending real money on the virtual paper trading platform.